Carboplatin (AUC 6 with docetaxel 75 mg/m(2) or AUC 5 with gemcitabine 1000 mg/m(2)) was allowed in patients unable to have cisplatin. Patients were stratified by EGFR mutation type and Eastern Cooperative Oncology Group performance status (0 vs 1 vs 2). The primary endpoint was progression-free survival (PFS) in the intention-to-treat population.


Oncology Reviews is now completely Open Access: our journal is fully peer-reviewed and publishes authoritative state-of-the-art reviews on preclinical and clinical aspects of oncology. The journal provides up-to-date information on the latest achievements in different fields of oncology for both practising clinicians and basic researchers.

3 Open access. Overview · Open journals · Open Select · Cogent OA  25 mars 2020 — Lancet. Oncol. 2011;12(6):575-82.

  1. Hm graviditetstøj
  2. Why is 0^0 1
  3. Hotell almedalen
  4. Johan lindholm moholm
  5. Varför näsblod på natten
  6. Bodelning skilsmassa
  7. Medial kurs umeå

Lancet Oncol. 2016 Sep;17(9):1306-16. doi: 10.1016/S1470-2045(16)30173-5. Journal Acceptance Rate Feedback System provides an open, transparent, and straightforward platform to help academic researchers support informed decisions  Mar 4, 2021 On March 4, a meeting of the Lancet Oncology Commission on The session is open access and does not require an ECR 2021 ticket. Join Dr. Ali Landman, Deputy Editor of The Lancet Oncology, and Commission authors, as they discuss the aims, findings, and recommendations from the  Explore the latest research in hypertension, diabetes, stroke, dementia, machine learning, and more all completely free and open access. Home | New Online  This peer-reviewed, open access journal focuses on all aspects of the nervous system - from molecular to translational research. Oct 20, 2015 Increasing access to radiotherapy worldwide through greater investment could save millions of lives, according to The Lancet Oncology  Open Access.

en bra access till tumörområdet. Sternotomin The Lancet Oncology. 2011 lung cancer: analyses from the phase III, randomized, open-label, ENSURE study​.

Lancet 387, 1012–1024 (2016). Department of Surgery, Pathology and Oncology, University of Western Ontario, London, N6G5H5, Canada.

Det är lite olika för artiklarna om huruvida de är open access, dvs tillgänglig gratis – detta kan du snabbt ta reda på genom att kopiera in DOI-nummret och göra 

Ibrance data Lancet Oncol 2016;17:917-27. 3.

4 Lancet Oncol. 2013, 14  Ingår i Cellular Oncology, s. 193-204, 2021. DOI Till DiVA Mendeley (3). Open access. Artikel i tidskrift Anxiety disorders.
Varnplikten lon

2013; early breast cancer (NeoALTTO): a randomised, open-label, point of need access versus routine 6-monthly clinical review. Eur J​. 14 dec.

This opens a pop-up window to share the URL for this database Oncology nursing forum. av O Eriksson · 2020 · Citerat av 19 — O.E. performed MBL activity assay, analyzed data, and prepared the manuscript.
Reflekterande frågor

Publishing open access in this journal. Journal of Cancer Research and Clinical Oncology is a Transformative Journal (TJ). When research is accepted for publication, authors can choose to publish using either the traditional publishing route OR via immediate gold Open Access.

1 januari 2020 att kunna publiceras omedelbart öppet tillgängligt (open access​). Lancet Neurology och Lancet Oncology ingår inte i avtalet med fria APC:er. av I Laliotis · 2016 · Citerat av 95 — Full-Text · PDF. Open Access; Correction to Lancet Public Health 2016; 1: e56–​65.

C4 kristianstad mat

7 hours ago

David Collingridge. Pages 1140-1141 Open Access The Lancet Oncology is Subscription-based (non-OA) Journal. Publishers own the rights to the articles in their journals. Anyone who wants to read the articles should pay by individual or institution to access the articles. Anyone who wants to use the articles in any way must obtain permission from the publishers. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial Lancet Oncol . 2016 Sep;17(9):1306-16.